Replies to post #179777 on Biotech Values

[DewDiligence]

NVS advances ENTA’s EDP-239 into DDI study with NVS’ Alisporvir in healthy volunteers:

http://finance.yahoo.com/news/enanta-pharmaceuticals-hcv-ns5a-inhibitor-123000111.html

Following the DDI study, NVS will conduct a phase-2b trial of EDP-239 + Alisporvir in HCV patients, at which point ENTA will earn a $15M milestone payment.

All told, ENTA is eligible to receive $395M in pre-commercial milestone payments from NVS (including the above $15M) and $160M in commercial milestones.